“绿十字”是日本最富有创新精神的医药公司之一。该公司一个经理曾在一个文件上篡改了日期,致使一个新药品在检查员那儿蒙混过了关。去年,这个丑闻被揭发出来,公司的声誉一跃千丈。现在,这家公司正在重整旗鼓,准备好再度接经检验。人们有充分理由相信,这一次一定能够堂堂正正地通过。但是,该公司将为自己的过失付出昂贵的代价,很可能是减少几年的收入;而世界也将为此付出代价——人造血问世的时间将会推迟。 Green Cross is one of Japan’s most innovative pharmaceutical companies. A manager at the company had tampered with the date on a document, causing a new drug to be overshadowed by the inspector. Last year, the scandal was revealed and the company’s reputation ballooned. Now, the company is regrouping and ready to undergo another test. People have every reason to believe that this time they will certainly be able to adopt it openly. However, the company will pay an exorbitant price for its own mistakes, most likely to reduce revenues for several years; and the world will pay for it - the time it takes for humanoid blood to be delayed.